Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice

Journal of Crohn's and Colitis

Volumn 7, Issue 11, 2013, Pages

  Sugiura, Toshihiko ^a   Kageyama, Shunsuke ^a   Andou, Ayatoshi ^a   Miyazawa, Tomoko ^a   Ejima, Chieko ^a   Nakayama, Akira ^a   Dohi, Taeko ^b   Eda, Hiroyuki ^a  

^a AJINOMOTO CO INC   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

4 Integrin antagonist; AJM300; Inflammatory bowel disease; Lymphocyte homing; Oral drug

Indexed keywords

AJM 300; AJM300; ALPHA4 INTEGRIN; ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; INTERLEUKIN 10; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LAMINA PROPRIA; LYMPHOCYTE COUNT; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; T LYMPHOCYTE; WEIGHT GAIN;

4′,6-DIAMIDINO-2-PHENYLINDOLE; A SPECIAL FORMULATION CONTAINING AJM300 AT APPROXIMATELY 43% AND EXCIPIENTS: AJM300M1 PREPARATION; AJM300; AJM300M1; CONTROL; CTRL; DAPI; HEK; HUMAN EMBRYONIC KIDNEY; IBD; ICAM-1; IL-10; INFLAMMATORY BOWEL DISEASE; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; LYMPHOCYTE HOMING; MADCAM-1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1; ORAL DRUG; ORALLY ACTIVE SMALL MOLECULE Α4 INTEGRIN ANTAGONIST; PBS; PD; PHARMACODYNAMICS; PHARMACOKINETICS; PHOSPHATE-BUFFERED SALINE; PK; SCID; SEVERE COMBINED IMMUNO-DEFFICIENT; VASCULAR CELL ADHESION MOLECULE-1; VCAM-1; Α4 INTEGRIN ANTAGONIST;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; CELL ADHESION MOLECULES; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA4; MALE; MICE; MICE, INBRED BALB C; PHENYLALANINE; QUINAZOLINONES; RANDOM ALLOCATION; REFERENCE VALUES;

EID: 84884816010     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.014     Document Type: Article

References (52)

1. Khor B., Gardetl A., Xavierl R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
2. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
3. Arihiro S., Ohtani H., Suzuki M., Murata M., Ejima C., Oki M., et al. Differential expression of mucosal addressin cell adhesion molucule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int 2002, 52:367-374.
4. González-Amaro R., Mittelbrunn M., Sánchez-Madrid F. Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?. Immunology 2005, 116:289-296.
5. Briskin M., Winsor-Hines D., Shyjan A., Cochran N., Bloom S., Wilson J., et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997, 151:97-110.
6. Rivera-Nieves J., Gorfu G., Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1715-1735.
7. Podolsky D.K., Lobb R., King N., Benjamin C.D., Pepinsky B., Sehgal P., et al. Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993, 92:372-380.
8. Hesterberg P.E., Winsor-Hines D., Briskin M.J., Soler-Ferran D., Merrill C., Mackay C.R., et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 1996, 111:1373-1380.
9. Rivera-Nieves J., Olson T., Bamias G., Bruce A., Solga M., Knight R.F., et al. L-selectin, α4β1 and α4β7 integrins participate in CD4 T cell recruitment to chronically inflamed small intestine. J Immunol 2005, 174:2343-2352.
10. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
11. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
12. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Parě P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 2005, 352:2499-2507.
13. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol 2008, 6:1370-1377.
14. Stefanich E.G., Danilenko D.M., Wang H., O'Byrne S., Erickson R., Gelzleichter T., et al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011, 162:1855-1870.
15. Rutgeerts P.J., Fedorak R.N., Hommes D.W., Sturm A., Baumgart D.C., Bressler B., et al. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut Jun 20 2012, [Epub ahead of print].
16. Vermeire S., Ghosh S., Panes J., Dahlerup J.F., Luegering A., Sirotiakova J., et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011, 60:1068-1075.
17. Gisbert J.P., Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
18. Hijazi Y., Welker H., Dorr A.E., Tang J.P., Blain R., Renzetti L.M., et al. Pharmacokinetics, safety, and tolerability of R411, a dual α4β1-α4β7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol Ther 2004, 44:1368-1378.
19. Davenport R.J., Munday J.R. Alpha4-integrin antagonism - an effective approach for the treatment of inflammatory diseases?. Drug Discov Today 2007, 12:569-576.
20. Tilley J.W. Very late antigen-4 integrin antagonists. Expert Opin Ther Pat 2008, 18:841-859.
21. Makino S, Okuzumi T, Yoshimura T, Satake Y, Suzuki N, Izawa H, et al. 2002; WO200216329.
22. Ghosh S., Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol 2010, 3:239-258.
23. Villablanca E.J., Cassani B., von Andrian U.H., Mora J.R. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 2011, 140:1776-1784.
24. Thomas S., Baumgart D.C. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012, 20:1-18.
25. Ikenoue Y., Tagami T., Murata M. Development and validation of a novel IL-10 deficient cell transfer model for colitis. Int Immunopharmacol 2005, 5:993-1006.
26. Andou A., Hisamatsu T., Okamoto S., Chinen H., Kamada N., Kobayashi T., et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009, 136:564-574.
27. Iizuka T., Tanaka T., Suematsu M., Miura S., Watanabe T., Koike R., et al. Stage-specific expression of mucosal addressin cell adhesion molecule-1 during embryogenesis in rats. J Immunol 2000, 164:2463-2471.
28. Moyano J.V., Carnemolla B., Domínguez-Jiménez C., García-Gila M., Albar J.P., Sánchez-Aparicio P., et al. Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated α4β1 and α4β1 integrins. J Biol Chem 1997, 272:24832-24836.
29. Sigal A., Bleijs D.A., Grabovsky V., van Vliet S.J., Dwir O., Figdor C.G., et al. The LFA-1 integrin supports rolling adhesions on ICAM-1 under physiological shear flow in a permissive cellular environment. J Immunol 2000, 165:442-452.
30. Egger L.A., Kidambi U., Cao J., Van Riper G., McCauley E., Mumford R.A., et al. α4β7/α4β1 dual integrin antagonists block α4β7-dependent adhesion under shear flow. J Pharmacol Exp Ther 2002, 302:153-162.
31. Chen L.L., Whitty A., Lobb R.R., Adams S.P., Pepinsky R.B. Multiple activation states of integrin α4β1 detected through their different affinities for a small molecule ligand. J Biol Chem 1999, 274:13167-13175.
32. Palecanda A., Marshall J.S., Li X., Briskin M.J., Issekutz T.B. Selective antibody blockade of lymphocyte migration to mucosal sites and mast cell adhesion. J Leukoc Biol 1999, 65:649-657.
33. Altevogt P., Hubbe M., Ruppert M., Lohr J., von Hoegen P., Sammar M., et al. The α4 integrin chain is a ligand for α4β7 and α4β1. J Exp Med 1995, 182:345-355.
34. Erle D.J., Briskin M.J., Butcher E.C., Garcia-Pardo A., Lazarovits A.I., Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leukocytes. J Immunol 1994, 153:517-528.
35. Miyake K., Irving L.W., Joel S.G., Paul W.K. Evidence for a role of the integrin VLA4 in lympho-hemopoiesis. J Exp Med 1991, 173:599-607.
36. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996, 184:241-251.
37. Shaw S.K., Ma S., Kim M.B., Rao R.M., Hartman C.U., Froio R.M., et al. Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 accompany neutrophil transmigration. J Exp Med 2004, 200:1571-1580.
38. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
39. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
40. Clifford D.B., De Luca A., Simpson D.M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
41. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366:1870-1880.
42. Fox R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med 2011, 78:S33-S37.
43. Sheremata W.A., Vollmer T.L., Stone L.A., Willmer-Hulme A.J., Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999, 52:1072-1074.
44. Fedyk E.R., Wyant T., Yang L.L., Csizmadia V., Burke K., Yang H., et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012, 18:2107-2119.
45. Parikh A., Leach T., Wyant T., Scholz C., Sankoh S., Mould D.R., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012, 8:1470-1479.
46. Hamann A., Andrew D.P., Jablonski-Westrich D., Holzmann B., Butcher E.C. Role of α4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994, 152:3282-3293.
47. Issekutz T.B. Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody. A likely role for VLA-4 in vivo. J Immunol 1991, 147:4178-4184.
48. Leone D.R., Giza K., Gill A., Dolinski B.M., Yang W., Perper S., et al. An assessment of the mechanistic differences between two integrin α4β1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2003, 305:1150-1162.
49. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., et al. Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
50. Gordon F.H., Lai C.W.Y., Hamilton M.I., Allison M.C., Srivastava E.D., Fouwether M.G., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001, 121:268-274.
51. Gordon F.H., Hamilton M.I., Donoghue S., Greenlees C., Palmer T., Rowley-Jones D., et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699-705.
52. Takazoe M., Watanabe M., Kawaguchi T., Matsumoto T., Oshitani N., Hiwatashi N., et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease-a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 136:A181.